Text and Data Mining valid from 2018-04-13
Received: 12 June 2017
Accepted: 4 April 2018
First Online: 13 April 2018
: The study was performed as a part of the trial entitled “Immunoexpression of DNA Fragmentation Factors 40 (DFF40), 45 (DFF45) and B-cell lymphoma 2 (BCL2) in normal human endometrium and uterus myometrium, non-malignant endometrial and myometrial disorders and in epithelial and non-epithelial malignancies of uterus in correlation with clinical and pathological characteristics.” This trial resulted in a former publication describing DFF45, BCL2 and DF40 expression in endometrial polyps, benign simple hyperplasia and uterus leiomyomas and leiomyosarcomas [CitationRef removed, CitationRef removed]. We previously developed and validated the methodology, including immunohistochemistry with DFF40, BCL2 and DFF45 staining and scoring, that was used in the present study to obtain comparable outcomes to our formerly published results.
: The study was approved by the Jagiellonian University Ethics Board (decision no: 122.6120.360). This was a retrospective study of paraffin-embedded specimens and archived, de-identified clinical data. All the data were fully anonymous thus, the Jagiellonian University Ethics Board waived the need for obtaining patients’ informed consents. The study was conducted in accordance with the guidelines of the Declaration of Helsinki.
: All authors declare that they have no competing interests.
: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.